{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:15Z","timestamp":1790876655681,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1002\/jps.24690","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T06:34:51Z","timestamp":1446014091000},"page":"2677-2684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans"],"prefix":"10.1016","volume":"105","author":[{"given":"Bart","family":"Hens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Corsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24690_bib1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1128\/AAC.43.2.322","article-title":"Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice","volume":"43","author":"Connolly","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib2","doi-asserted-by":"crossref","first-page":"e83247","DOI":"10.1371\/journal.pone.0083247","article-title":"In\u00a0vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis","volume":"8","author":"de Macedo-Silva","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/jps.24690_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10096-015-2340-y","article-title":"Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia","volume":"34","author":"D\u00f6ring","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/jps.24690_bib4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.41.7.1558","article-title":"Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis","volume":"41","author":"Lutz","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib5","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In\u00a0vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.40.8.1910","article-title":"In\u00a0vitro and in\u00a0vivo efficacies of the azole SCH56592 against Cryptococcus neoformans","volume":"40","author":"Perfect","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.40.5.1314","article-title":"In\u00a0vitro and in\u00a0vivo activities of SCH 56592 against Blastomyces dermatitidis","volume":"40","author":"Sugar","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib9","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib10","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jps.2600710120","article-title":"Theoretical and experimental studies of transport of micelle-solubilized solutes","volume":"71","author":"Amidon","year":"1982","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1002\/jps.24690_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J"},{"key":"10.1002\/jps.24690_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.24690_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.24690_bib17","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1002\/jps.24690_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1002\/jps.24690_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2012.11.026","article-title":"Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues","volume":"453","author":"Bevernage","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.24690_bib20","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s11095-010-0213-8","article-title":"Predicting intestinal precipitation\u2014A case example for a basic BCS class II drug","volume":"27","author":"Carlert","year":"2010","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24690_bib21","unstructured":"Brouwers J, Augustijns P. Biorelevant evaluation of supersaturation and precipitation inhibition: do we understand the gastrointestinal environment? Bulletin Technique Gattefoss\u00e9: Vol. 104. Journ\u00e9es Gal\u00e9niques. Saint-R\u00e9my de Provence, France, 16-18 June 2011:71-82."},{"key":"10.1002\/jps.24690_bib22","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24690_bib23","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/jps.23494","article-title":"Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine","volume":"102","author":"Culen","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1002\/jps.24690_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A\u00a0review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.24690_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejps.2014.07.008","article-title":"Gastrointestinal transfer: in\u00a0vivo evaluation and implementation in in\u00a0vitro and in silico predictive tools","volume":"63","author":"Hens","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.24690_bib26","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib27","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24690_bib28","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A\u00a0new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1002\/jps.24690_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12281-014-0185-y","article-title":"Update on posaconazole pharmacokinetics: comparison of old and new formulations","volume":"8","author":"Percival","year":"2014","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1002\/jps.24690_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-015-0348-3","article-title":"Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"10.1002\/jps.24690_bib31","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1021\/mp400658k","article-title":"Effect of precipitation inhibitors on indomethacin supersaturation maintenance: mechanisms and modeling","volume":"11","author":"Patel","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.24690_bib32","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1021\/mp300576u","article-title":"Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component analysis","volume":"10","author":"Warren","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.24690_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.05.013","article-title":"Drug precipitation inhibitors in supersaturable formulations","volume":"453","author":"Xu","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.24690_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejpb.2011.04.005","article-title":"Precipitation in the small intestine may play a more important role in the in\u00a0vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir","volume":"79","author":"Shono","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.24690_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In\u00a0vitro models for the prediction of in\u00a0vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.24690_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejps.2013.10.012","article-title":"Oral biopharmaceutics tools\u2014Time for a new initiative\u2014An introduction to the IMI project OrBiTo","volume":"57","author":"Lennern\u00e4s","year":"2014","journal-title":"Eur J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T01:42:24Z","timestamp":1567302144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0022354915001173"],"URL":"https:\/\/doi.org\/10.1002\/jps.24690","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}